ATAI
Price
$2.33
Change
+$0.11 (+4.95%)
Updated
Jun 18, 04:59 PM (EDT)
Capitalization
491.04M
61 days until earnings call
SCPH
Price
$3.91
Change
-$0.08 (-2.01%)
Updated
Jun 18, 04:59 PM (EDT)
Capitalization
206.94M
49 days until earnings call
Interact to see
Advertisement

ATAI vs SCPH

Header iconATAI vs SCPH Comparison
Open Charts ATAI vs SCPHBanner chart's image
ATAI Life Sciences
Price$2.33
Change+$0.11 (+4.95%)
Volume$13.77K
Capitalization491.04M
scPharmaceuticals
Price$3.91
Change-$0.08 (-2.01%)
Volume$2.1K
Capitalization206.94M
ATAI vs SCPH Comparison Chart in %
Loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATAI vs. SCPH commentary
Jun 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a Hold and SCPH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 19, 2025
Stock price -- (ATAI: $2.33 vs. SCPH: $3.99)
Brand notoriety: ATAI and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATAI: 147% vs. SCPH: 72%
Market capitalization -- ATAI: $491.04M vs. SCPH: $206.94M
ATAI [@Biotechnology] is valued at $491.04M. SCPH’s [@Biotechnology] market capitalization is $206.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $335.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, ATAI is a better buy in the long-term than SCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 5 TA indicator(s) are bullish while SCPH’s TA Score has 5 bullish TA indicator(s).

  • ATAI’s TA Score: 5 bullish, 5 bearish.
  • SCPH’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SCPH is a better buy in the short-term than ATAI.

Price Growth

ATAI (@Biotechnology) experienced а +4.48% price change this week, while SCPH (@Biotechnology) price change was -6.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.32%. For the same industry, the average monthly price growth was +13.75%, and the average quarterly price growth was +8.90%.

Reported Earning Dates

ATAI is expected to report earnings on Aug 18, 2025.

SCPH is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATAI($491M) has a higher market cap than SCPH($207M). ATAI YTD gains are higher at: 75.188 vs. SCPH (10.734). SCPH has higher annual earnings (EBITDA): -83.9M vs. ATAI (-145.09M). ATAI has more cash in the bank: 98.2M vs. SCPH (57.5M). ATAI has less debt than SCPH: ATAI (26.7M) vs SCPH (52.4M). SCPH has higher revenues than ATAI: SCPH (42M) vs ATAI (1.86M).
ATAISCPHATAI / SCPH
Capitalization491M207M237%
EBITDA-145.09M-83.9M173%
Gain YTD75.18810.734700%
P/E RatioN/AN/A-
Revenue1.86M42M4%
Total Cash98.2M57.5M171%
Total Debt26.7M52.4M51%
FUNDAMENTALS RATINGS
ATAI vs SCPH: Fundamental Ratings
ATAI
SCPH
OUTLOOK RATING
1..100
7316
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3640
P/E GROWTH RATING
1..100
14100
SEASONALITY SCORE
1..100
8710

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCPH's Valuation (61) in the Pharmaceuticals Major industry is in the same range as ATAI (66) in the Miscellaneous Commercial Services industry. This means that SCPH’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Profit vs Risk Rating (95) in the Miscellaneous Commercial Services industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that ATAI’s stock grew similarly to SCPH’s over the last 12 months.

ATAI's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that ATAI’s stock grew similarly to SCPH’s over the last 12 months.

ATAI's Price Growth Rating (36) in the Miscellaneous Commercial Services industry is in the same range as SCPH (40) in the Pharmaceuticals Major industry. This means that ATAI’s stock grew similarly to SCPH’s over the last 12 months.

ATAI's P/E Growth Rating (14) in the Miscellaneous Commercial Services industry is significantly better than the same rating for SCPH (100) in the Pharmaceuticals Major industry. This means that ATAI’s stock grew significantly faster than SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATAISCPH
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 14 days ago
81%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JLVIX71.28N/A
N/A
JHancock Fundamental Large Cap Core I
FIUSX32.32N/A
N/A
Macquarie Opportunity A
SAMVX11.29N/A
N/A
Virtus Ceredex Mid-Cap Value Equity A
SUSTX14.73N/A
N/A
Lazard US Sustainable Equity Inst
REAYX23.60-0.20
-0.84%
Russell Inv Equity Income Y

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with CRSP. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
-1.75%
CRSP - SCPH
45%
Loosely correlated
+2.87%
BEAM - SCPH
44%
Loosely correlated
+1.92%
AURA - SCPH
44%
Loosely correlated
-1.29%
YMAB - SCPH
43%
Loosely correlated
-3.54%
ATAI - SCPH
43%
Loosely correlated
+4.95%
More